WHO ICTRP trial
Impact of MET Gene Abnormalities on the Efficacy of Anti-HER2 Targeted Therapy…
ChiCTR2600117225 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600117225 |
|---|---|
| Public title | Impact of MET Gene Abnormalities on the Efficacy of Anti-HER2 Targeted Therapy in Chinese Gastric Cancer Patients: A Multicenter, Retrospective Cohort Study |
| Scientific title | Impact of MET Gene Abnormalities on the Efficacy of Anti-HER2 Targeted Therapy in Chinese Gastric Cancer Patients: A Multicenter, Retrospective Cohort Study |
| Primary sponsor | Shanghai East Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Countries | China |
| Conditions | Gastric cancer |
| Interventions | Observation group for gastric cancer treatment:None |
| Registration date | Jan 21, 2026 |
| Target size | Observation group for gastric cancer treatment:420 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: